Orchestra BioMed: Nearing The First Of Two Pivotal Readouts
Orchestra Biomed Holdings Inc OBIO
$3.98
▼ -0.25%
($-0.01)
🗓️ Earnings Next Week
Open
$3.98
Prev Close
$3.99
Day Range
$3.84 – $4.06
52W Range
$2.20 – $5.42
Market Cap
$238.33M
Beta
0.51
EPS (TTM)
$-1.13
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-08-04 |
| Shares Out. | 59,880,000 |
| Website | orchestrabiomed.com ↗ |
| Phone | 16463439298 |
| Employees | 86 |
| Revenue | $110,000 |
| Gross Profit | $78,000 |
| Net Income | -$20.7M |
| Free Cash Flow | -$55.1M |
| Total Assets | $100.7M |
| Total Liabilities | $49.7M |
| Equity | $41.2M |
About Orchestra Biomed Holdings Inc
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
Orchestra Biomed Holdings Inc is a publicly traded company under the ticker symbol OBIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)